SILO Pharma (SILO) Gains 53%
For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun.
Silo Pharma Gains 53%...
Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Society Pass (SOPA) $1.15 Breaks Above First Line of Resistance.
If you're familiar with the term, "..the stars are aligning" here is a real life example. If you're familiar with the term,...
Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.
Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion)...
Three That Doubled, Three More That May Double.
Ardelyx $3.00 (ARDX) Gains 117%, Provention Bio $8.75 (PRVB) Gains 134%, and PharmaTher (PHRRF) up 154%. Blue Skies Ahead - For All...
Society Pass (SOPA) Research Reports
RESEARCH REPORT ARCHIVE
December 27th, 2023. Litchfield Hills Research - $4.00 Price Target.
Adding Society Pass (SOPA) $0.96 to the Watch List
Amazing Fast Grower, in the Asian Silicon Valley.
After a wildly successful IPO debut and subsequent tumble, Society...
PNF Accountants & Advisors Cocktail Hour!
Thursday, 6:00 PM at Hagerty Garage & Social
Tonya Notaro
Hagerty...
Ouch, for Now. Progressive Care Does 200:1 Reverse.
MASSIVE REVERSE SPLIT
Let's just watch from the sidelines for...
Silo Pharma (SILO) Trades up 90% Friday, With 23 Million Shares Traded!
And We Weren't Watching!
It was Friday after all, and the last day of the year, and we were...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
